Years ago, I used to teach public relations courses called Reputation Management to corporate suits. When I singled out companies that had somehow managed to weather bad press to emerge with reputations well intact, there was one at the top.
That company poster child was, hands down, Johnson & Johnson.
In fact, for many years the Forbes list of 100 Most Admired Companies featured J&J as their perennial list-topper. And the exemplary way the company had swiftly stick-handled its catastrophic Tylenol murders scandal in 1982 continues to be taught in PR, journalism and crisis communications classes.
But those heady days must seem far, far away now, with increasing reports of tainted J&J drug recalls. As Consumer Reports Health describes it, a nauseatingly bad smell to its products has been blamed for stinking up several different types of Tylenol, the antipsychotic drug Risperdal, HIV/AIDS drug Prezista, and two lots of the anti-epilepsy drug Topamax among many others. In fact, the agency reports that recalls like these have cost J&J almost $900 million in sales last year alone. Continue reading